ZEVRA THERAPEUTICS, INC. (ZVRA) Form 10-Q — Aug 5, 2026
Zevra Therapeutics reported Q2 2026 revenue of $39.7 million, up 53% from $25.9 million a year ago, driven by MIPLYFFA sales of $30.2 million and $9.0 million of expanded-access revenue. Net income was $8.8 million, or $0.14 per diluted share, versus $74.7 million in Q2 2025, which had included a one-time $148.3 million gain on the sale of its priority review voucher. The balance sheet strengthened markedly: the company repaid its roughly $63.1 million term loans in full in March 2026, incurring $7.2 million in make-whole and $1.8 million in final premiums, and ended the quarter debt-free with $145.3 million in cash and first-half operating cash flow of $23.2 million.
Key figures
- Eps
- 0.14
- Revenue
- 39663000
- Net Income
- 8752000
- Total Debt
- 0
- Revenue Yoy
- +53.2% (Q2 2026 vs Q2 2025)
- Total Assets
- 302712000
- Cash Position
- 145321000
- Shares Outstanding
- 59383781
- Eap revenue q2
- 9000000
- Miplyffa q2 sales
- 30200000
- Six month revenue
- 75883000
- Warrant liability
- 13165000
- Six month net income
- 46642000
- Final payment premium
- 1800000
- Six month eps diluted
- 0.74
- Six month revenue yoy
- +64.0%
- Debt repaid march 2026
- 63100000
- Gain on sdx asset sale
- 43314000
- Commave settlement total
- 50000000
- Miplyffa six month sales
- 54900000
- Total stockholders equity
- 217652000
- Clawback reserve liability
- 18600000
- Loss on debt extinguishment
- 2756000
- Operating cash flow six month
- 23174000
- Make whole and prepayment premium
- 7200000
Price after filing
Close on the filing date to close N calendar days later (from $10.52). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.